Abstract
The disinfection of air using Germicidal Ultraviolet light (GUV) is a long-standing technique, which has received increasing attention during the COVID-19 pandemic. GUV uses UVC lamps as its light source, which are known to inactivate microorganisms by damaging their genetic material. But they also initiate photochemistry in air. However, the impact of GUV on indoor air quality and chemistry has not been investigated in detail, to our knowledge. In this study, we model the chemistry initiated by GUV at 254 or 222 nm (“GUV254” or “GUV222”) in a typical room with typical indoor pollutant levels, and for different ventilation levels. GUV254 is irritating for skin and eyes, has an occupational exposure limit, and thus these fixtures typically irradiate a smaller volume near the ceiling, or inside ventilation ducts. In contrast, GUV222 is described by some as harmless to skin or eyes due to rapid absorption in a very thin external layer. Our analysis showed that GUV254 is able to significantly photolyze O3, generating OH radicals, which initiates the oxidation of almost all indoor volatile organic compounds (VOCs). While secondary organic aerosol (SOA) can be formed as a product of VOC oxidation, most of the SOA in our case studies is produced through GUV-independent terpene ozonolysis. GUV254-induced SOA formation is of the order of 0.1-1 μg m-3. GUV222 with the same effective virus removal rate makes a smaller impact on indoor air quality at mid to high ventilation rates, mainly because of the significantly lower UV irradiance needed and thus substantially less efficient O3 photolysis (for primary OH generation) than at 254 nm. GUV222 has a higher impact than GUV254 when ventilation is poor due to a small but significant photochemical production of O3 at 222 nm, which does not happen with GUV254.
Synopsis Germicidal ultraviolet light initiates indoor oxidation chemistry, potentially forming indoor air pollutants. The amount is not negligible and depends on both the wavelength of light and the ventilation level.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ZP and JLJ were partially supported by the CIRES Innovative Research Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have improved the manuscript with a number of clarifications and one more sensitivity case.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
